Mileva, Magdalena http://orcid.org/0000-0002-9929-4576
de Vries, Elisabeth G. E.
Guiot, Thomas
Wimana, Zéna
Deleu, Anne-Leen
Schröder, Carolien P.
Lefebvre, Yolene
Paesmans, Marianne
Stroobants, Sigrid
Huizing, Manon
Aftimos, Philippe
Tol, Jolien
Van der Graaf, Winette T. A.
Oyen, Wim J. G.
Vugts, Danielle J.
Menke-van der Houven van Oordt, C. Willemien
Brouwers, Adrienne H. http://orcid.org/0000-0003-2698-1516
Piccart-Gebhart, Martine
Flamen, Patrick
Gebhart, Géraldine http://orcid.org/0000-0001-8853-0783
Funding for this research was provided by:
Academic trial with a grant provided by Roche.
Article History
Received: 12 May 2023
Accepted: 4 December 2023
First Online: 6 January 2024
Competing interests
: E.G.E.d.V. reports Institutional Financial Support for her advisory role from Crescendo Biologics, Daiichi Sankyo and NSABP, and Institutional Financial Support for clinical trials or contracted research from Amgen, Bayer, Crescendo Biologics, CytomX Therapeutics, G1 Therapeutics, Genentech, Regeneron, Roche, Servier and Synthon, all outside the submitted work. P.A. is consultant for Boehringer Ingelheim, Macrogenics, Roche, Novartis, Amcure, Servier, G1 Therapeutics, Radius and Deloitte, has received honoraria from Synthon, Amgen, Novartis, Gilead, Lilly and Menarini, travel grants from Amgen, MSD, Pfizer, Roche and Daiichi Sankyo, and institutional research funding from Roche. W.V.d.G. has received institutional financial support for serving in the advisory board of Agenus, SpringworksTx and PTC Therapeutics, and has received institutional grant from Eli Lilly. W.O. is part of the advisory boards at Novartis/AAA and Bayer, and has received speaker’s fee from Astellas. M.P.G. is part of the scientific board at Oncolytics, has received honoraria for consultant roles for AstraZeneca, Camel-IDS/Precirix, Gilead, Immunomedics, Lilly, Menarini, MSD, Novartis, Pfizer, Roche-Genentech, Seattle Genetics, Seagen, NBE Therapeutics and Frame Therapeutics, and received institutional grants from AstraZeneca, Immunomedics, Lilly, Menarini, MSD, Novartis, Pfizer, Radius, Roche-Genentech, Servier and Synthon. All other authors report no competing interests.